Calcitonin inhibits invasion of breast cancer cells: Involvement of urokinase-type plasminogen activator (uPA) and uPA receptor

International Journal of Oncology

Volumn 28, Issue 4, 2006, Pages 807-814

  Han, Bo ^a,b   Nakamura, Misa ^a   Zhou, Gengyin ^b   Ishii, Aiko ^a   Nakamura, Atsushi ^a   Bai, Yanhua ^a,b   Mori, Ichiro ^a   Kakudo, Kennichi ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Breast cancer; Calcitonin; Invasion; uPAR; Urokinase plasminogen activator

Indexed keywords

CALCITONIN; CELL SURFACE RECEPTOR; DNA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR, UROKINASE RECEPTORS; UROKINASE;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BIOSYNTHESIS; BREAST TUMOR; CANCER INVASION; CELL MOTION; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOUSE; NORTHERN BLOTTING; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; BREAST NEOPLASMS; CALCITONIN; CELL LINE, TUMOR; CELL MOVEMENT; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; URINARY PLASMINOGEN ACTIVATOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33744733066     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.4.807     Document Type: Article

References (37)

1. Chambers TJ and Magnus CJ: Calcitonin alters behaviour of isolated osteoclasts. J Pathol 136: 27-39, 1982.
2. Pondel M: Calcitonin and calcitonin receptors: bone and beyond. Int J Exp Pathol 81: 405-422, 2000.
3. Zaidi M, Inzerillo AM, Moonga BS, Bevis PJ and Huang CL: Forty years of calcitonin - where are we now? A tribute to the work of Iain Macintyre, FRS. Bone 30: 655-663, 2002.
4. Ismail PM, DeMayo FJ, Amato P and Lydon JP: Progesterone induction of calcitonin expression in the murine mammary gland. J Endocrinol 80: 287-295, 2004.
5. Ng KW, Livesey SA, Larkins RG and Martin TJ: Calcitonin effects on growth and on selective activation of type II isoenzyme of cyclic adenosine 3′:5′-monophosphate-dependent protein kinase in T 47D human breast cancer cells. Cancer Res 43: 794-800, 1983.
6. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC and Bellido T: Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104: 1363-1374, 1999.
7. Findlay DM, Raggatt LJ, Bouralexis S, Hay S, Atkins GJ and Evdokiou A: Calcitonin decreases the adherence and survival of HEK-293 cells by a caspase-independent mechanism. J Endocrinol 175: 715-725, 2002.
8. McPherson K, Steel CM and Dixon JM: ABC of breast diseases. Breast cancer epidemiology, risk factors, and genetics. Br Med J 321: 624-628, 2000.
9. International Agency for Research on Cancer. Cancer incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5. IARC Press, Lyon, 2001.
10. Andreasen PA, Kjoller L, Christensen L and Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22, 1997.
11. Rabbani SA and Xing RH: Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. Int J Oncol 12: 911-920, 1998.
12. Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, Graeff H and Schmitt M: Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis. Int J Oncol 13: 893-906, 1998.
13. Han B, Nakamura M, Mori I, Nakamura Y and Kakudo K: Urokinase-type plasminogen activator system and breast cancer. Oncol Rep 14: 105-112, 2005.
14. Jänicke F, Prechtl A, Thomssen C, et al: Randomized adjuvant therapy trial in high-risk lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen inhibitor type I. J Natl Cancer Inst 93: 913-920, 2001.
15. Look MP, van Putten WL, Duffy MJ, et al: Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94: 116-128, 2002.
16. Hayes DF, Bast RC, Desch CE, et al: Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88: 1456-1466, 1996.
17. Ossowski L, Russo-Payne H and Wilson EL: Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res 51: 274-281, 1991.
18. Guo Y, Higazi AA, Arakelian A, et al: A peptide derived from the non-receptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. FASEB J 14: 1400-1410, 2000.
19. Rabbani SA and Gladu J: Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Res 62: 2390-2397, 2002.
20. Aguirre Ghiso JA, Alonso DF, Farias EF, Gomez DE and De Kier Joffe EB: Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype. Eur J Biochem 263: 295-304, 1999.
21. Segawa N, Nakamura M, Nakamura Y, Mori I, Katsuoka Y and Kakudo K: Phosphorylation of mitogen-activated protein kinase is inhibited by calcitonin in DU145 prostate cancer cells. Cancer Res 61: 6060-6063, 2001.
22. Ma Z, Webb DJ, Jo M and Gonias SL: Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J Cell Sci 14: 3387-3396, 2001.
23. Seddighzadeh M, Zhou JN, Kronenwett U, et al: ERK signalling in metastatic human MDA-MB-231 breast carcinoma cells is adapted to obtain high urokinase expression and rapid cell proliferation. Clin Exp Metastasis 17: 649-654, 1999.
24. Nakamura M, Yang Q, Ozaki T, Nakamura Y, Yamasaki H, Mori I and Kakudo K: Induction of uPA but not NF-IL3A by calcitonin is dependent on Erk1/2 phosphorylation in porcine renal cell line LLC-PK1. Biochem Biophys Res Commun 290: 1483-1488, 2002.
25. Nakamura Y, Yasuoka H, Tsujimoto M, et al: Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer. Breast Cancer Res Treat 91: 125-132, 2005.
26. Guo Y, Pakneshan P, Gladu J, Slack A, Szyf M and Rabbani SA: Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion. J Biol Chem 277: 41571-41579, 2002.
27. Holst-Hansen C, Johannessen B, Hoyer-Hansen G, Romer J, Ellis V and Brunner N: Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis 14: 297-307, 1996. (Pubitemid 26246575)
28. Yang X, Wei LL, Tang C, Slack R, Mueller S and Lippman ME: Overexpression of KAI1 suppresses in vitro invasiveness and in vivo metastasis in breast cancer cells. Cancer Res 61: 5284-5288, 2001.
29. Rong H, Ji H, Tsai JA, Pernow Y and Bucht E: Calcitonin-suppressed expression of parathyroid hormone-related protein in breast cancer cells. Biochem Biophys Res Commun 265: 260-264, 1999.
30. Lacroix M, Siwek B and Body JJ: Breast cancer cell response to calcitonin: modulation by growth-regulating agents. Eur J Pharmacol 344: 279-286, 1998.
31. Lacroix M and Body JJ: Regulation of c-fos and c-jun expression by calcitonin in human breast cancer cells. Calcif Tissue Int 60: 513-519, 1997.
32. Gillespie MT, Thomas RJ, Pu ZY, Zhou H, Martin TJ and Findlay DM: Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers. Int J Cancer 73: 812-815, 1997.
33. Wang X, Nakamura M, Mori I, et al: Calcitonin receptor gene and breast cancer: quantitative analysis with laser capture microdissection. Breast Cancer Res Treat 83: 109-117, 2004.
34. Bartsch JE, Staren ED and Appert HE: Matrix metalloproteinase expression in breast cancer. J Surg Res 110: 383-392, 2003.
35. Sabbisetti VS, Chirugupati S, Thomas S, et al: Calcitonin increases invasiveness of prostate cancer cells: Role for cyclic AMP-dependent protein kinase A in calcitonin action. Int J Cancer 117: 551-560, 2005.
36. Chigurupati S, Kulkarni T, Thomas S and Shah G: Calcitonin stimulates multiple stages of angiogenesis by directly acting on endothelial cells. Cancer Res 65: 8519-8529, 2005.
37. Chakraborty M, Chatterjee D, Kellokumpu S, Rasmussen H and Baron R: Cell cycle-dependent coupling of the calcitonin receptor to different G proteins. Science 251: 1078-1082, 1991.